세계의 신경과 시장 : BCC 조사 개요

The global market for neurology is estimated to increase from $67.3 billion in 2024 to reach $94.8 billion by 2029, at a compound annual growth rate (CAGR) of 7.1% from 2024 through 2029.

The multiple sclerosis market for neurology is estimated to increase from $22.5 billion in 2024 to reach $27.2 billion by 2029, at a CAGR of 3.9% from 2024 through 2029.

The brain tumor market for neurology is estimated to increase from $2.9 billion in 2024 to reach $5.3 billion by 2029, at a CAGR of 12.6% from 2024 through 2029.

Report Scope

This report includes a market analysis of the therapeutics used to treat neurological conditions. The study outlines the market potential for neurology medications for both now and in the future. It also provides a thorough examination of the market's drivers, constraints, and pipeline medications, as well as the competitive landscape, laws, epidemiology of neurological disorders, mergers and acquisitions. Market forecasts through 2029 are also covered in the report.

The report breaks down neurology market shares according to various disease indications. Parkinson's disease, Alzheimer's disease, psychotic disorder, epileptic disorder, autism disorder, multiple sclerosis, brain tumor, and other diseases are the neurological disorders that make up the market segmentation. Therapeutics and regional analysis are covered in each disease segment.

Anti-Parkinson's medications are covered in the Parkinson's disease market. The market is divided into different drug classes such as dopaminergic, enzyme inhibitors, dopamine agonists and other anti-Parkinson's drugs based on drug class. Anti-Alzheimer medications are part of the Alzheimer's disease market, which is divided into segments according to respective mechanisms of action. The market is divided into two segments based on drug class: NMDA antagonists and AChE inhibitors. Antipsychotic medications are part of the market for psychotic diseases. The market is divided into different drug classes, including D2 partial agonists, D2/5HT2A antagonists, and D2 antagonists.

Anti-epileptic medications are included in the market for epileptic diseases. The market is divided into three segments based on drug class: first-generation, second-generation and third-generation. Autism spectrum disorder drugs are included in the market. Based on information on labels, the market is divided into drug categories: off-label pharmaceuticals and pharmaceuticals with an ASD label. Brain tumor treatments are included in the market for brain tumors. The market is divided into different types of therapy, such as targeted therapy and chemotherapy.

In order to provide an in-depth understanding of the market, profiles of market participants, competitive landscape, key competitors and respective market share are also part of this report. By geographical region, the market in this report is divided into four regions: North America, Europe, Asia-Pacific, and Rest of the World (RoW). For market estimates, data has been provided for 2023 as the base year, with forecasts for 2024 through 2029.

Report Includes

• 52 data tables and 59 additional tables
• Analyses of the global market trends for neurology therapeutics, with market revenue data (sales figures) for 2022, estimates for 2023, forecasts for 2024, and projected CAGRs through 2029
• Estimates of the market size and revenue growth prospects, along with a market share analysis by type of disorder, drug classification, mechanism of action, label information, end user and region
• Facts and figures pertaining to key market dynamics, technology advances, pipeline drugs, regulations, and the impact of macroeconomic factors
• Insights derived from the Porter's Five Forces model, as well as global supply chain and PESTLE analyses
• Pipeline analysis covering ongoing clinical trials and promising forthcoming neuroscience therapies in late stage
• Discussion of therapeutics used for treatment of neurological disorders, along with coverage of novel pipeline drugs, patent expiries of blockbuster drugs and new drug approvals
• A patent analysis, including key granted and published patents
• Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
• Company profiles of major players within the industry, including F. Hoffmann-La Roche Ltd., Novartis AG, UCB S.A, and Otsuka Holdings Co. Ltd.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary

Chapter 2 Market Overview

• Overview
• Porter's Five Forces Analysis
• Potential for New Entrants (Low to Moderate)
• Bargaining Power of Suppliers (Moderate to High)
• Bargaining Power of Buyers (Moderate)
• Threat of Substitute Products or Services (Moderate to High)
• Industry Rivalry (High)
• Medical Coding and Billing Challenges in Neurology
• Step Therapy
• Medicare Cuts
• Coding errors
• Use of Modifiers
• Documentation
• Coverage and Prior Authorization
• Compliance and Audits
• Reimbursement Rate and Denials
• Physician Payment Challenges
• Evaluation and Management (E/M) - Bill the Correct Level of Care
• Negotiating Contracts

Chapter 3 Market Dynamics

• Market Dynamics
• Market Drivers
• Growing Geriatric Population with Neurological Disorders
• Increasing Global Incidence of Neurological Disorders
• Government and NGO Initiatives in Creating Awareness
• Research Initiatives in Neurology
• Market Restraints
• Patent Expirations of Branded Drugs and Emergence of Generics
• Adverse Side Effects
• High Cost of Drug Development

Chapter 4 Emerging Trends and Pipeline Analysis

• Emerging Trends
• Precision Medicine in Neurological Disorders
• Gene Therapy for Neurological Disorders
• Neurodegeneration and Stem Cell Therapy
• Nanotechnology in Neuroscience
• Virtual Reality and Digital Therapeutics
• Conclusion
• Pipeline Analysis

Chapter 5 Regulatory Landscape

• Overview
• Cross-Disciplinary Value Story
• High-Quality Patient-Reported Outcome Data
• Impact of New EU and the U.S. Legislation
• Conclusion

Chapter 6 Market Segmentation Analysis

• Segmental Breakdown
• Market Analysis by Disease Indication
• Parkinson's Disease
• Alzheimer's Disease
• Psychotic Disorders
• Epileptic Disorder
• Autism Spectrum Disorder
• Brain Tumor
• Multiple Sclerosis
• Others
• Geographic Breakdown
• Market Analysis by Region
• North America
• Europe
• Asia-Pacific
• Rest of the World

Chapter 7 Competitive Intelligence

• Company Share Analysis of Anti-Parkinson's Drugs
• Company Share Analysis of Alzheimer's Disease Drugs
• Company Share Analysis of Antipsychotic Drugs
• Company Share Analysis of Anti-Epileptic Drugs
• Company Share Analysis of ASD Therapeutics
• Company Share Analysis of Brain Tumor Therapeutics
• Company Share Analysis of Multiple Sclerosis Therapeutics

Chapter 8 Appendix

• Methodology
• Sources
• Abbreviations
• Company Profiles
• ABBVIE INC.
• ALPHA COGNITION
• BIOGEN
• BOEHRINGER INGELHEIM INTERNATIONAL GMBH
• BRISTOL-MYERS SQUIBB CO.
• EISAI CO. LTD.
• F. HOFFMANN-LA ROCHE LTD.
• H. LUNDBECK A/S
• LILLY
• MERCK & CO. INC.
• NOVARTIS AG
• OTSUKA HOLDINGS CO. LTD.
• SANOFI
• TEVA PHARMACEUTICAL INDUSTRIES LTD.
• UCB S.A.